XTalks

AUGUST 16, 2021

The US Food and Drug Administration (FDA) has amended its emergency use authorizations (EUA) for both the Pfizer and Moderna COVID-19 vaccines to incorporate a third dose for immunocompromised individuals. A small study from John Hopkins University has shown that a third dose of a COVID-19 vaccine could indeed help immunocompromised patients.

Vaccination 104

Vaccination Vaccine Antibody Immune Response 104

XTalks

NOVEMBER 16, 2020

Moderna announced today that its highly anticipated COVID-19 vaccine candidate appears to be 94.5 The news comes shortly after Pfizer and BioNTech’s mega announcement last week of their COVID-19 vaccine having shown 90 percent efficacy in an ongoing large-scale Phase III trial. The vaccine is given in two doses.

Vaccination 105

Vaccination Vaccine Trials Allergies 105

Scienmag

SEPTEMBER 30, 2020

Credit: Stefan Zimmerman Women vaccinated against HPV have a significantly lower risk of developing cervical cancer, and the positive effect is most pronounced for women vaccinated at a young age. That is according to a large study by researchers at Karolinska Institutet in Sweden published in New England Journal of Medicine.

Vaccination 97

Vaccination Vaccine Medicine Development 97

Medical Xpress

APRIL 13, 2023

In November 2022, the National Institute of Allergy and Infectious Diseases (NIAID) co-hosted a virtual workshop on the importance and challenges of developing mucosal vaccines for SARS-COV-2. The highlights of this workshop have now been published as a report in npj Vaccines.

Vaccination 75

Vaccination Vaccine Allergies Development 75

XTalks

SEPTEMBER 8, 2020

Albany Molecular Research Inc (AMRI), a global provider of advanced drug development and manufacturing solutions, announced that they have signed a supply agreement with AstraZeneca. The company has signed on to help manufacture AstraZeneca’s COVID-19 vaccine candidate, AZD1222, intended to protect against the SARS-CoV-2 novel coronavirus.

Manufacturing 83

Manufacturing Vaccination Vaccine Allergies 83

XTalks

AUGUST 13, 2020

As the rush for a COVID-19 vaccine continues, healthcare services company Kaiser Permanente has joined in on the clinical testing of Pfizer Inc. and BioNTech’s lead vaccine candidate in a Phase III trial being conducted at sites in California and Oregon.

Vaccination 89

Vaccination Vaccine Trials Clinical Trials 89

XTalks

MAY 11, 2022

The US Food and Drug Administration (FDA) announced last week that it has limited the authorized use of Janssen/Johnson & Johnson’s COVID-19 vaccine for individuals 18 years of age and older for whom other authorized or approved vaccines are not accessible or clinically appropriate.

Vaccination 98

Vaccination Vaccine Sales Allergies 98

Pfizer

JULY 26, 2022

Pfizer and BioNTech Advance COVID-19 Vaccine Strategy With Study Start of Next-Generation Vaccine Candidate Based on Enhanced Spike Protein Design. Pfizer and BioNTech Advance COVID-19 Vaccine Strategy With Study Start of Next-Generation Vaccine Candidate Based on Enhanced Spike Protein Design. deliesschef.

Vaccination 111

Vaccination Vaccine Protein Immune Response 111

Scienmag

NOVEMBER 4, 2020

The finding provides a surrogate for testing the effectiveness of vaccine candidates Credit: Jennifer Jenks, Duke University School of Medicine DURHAM, N.C.

Vaccination 63

Vaccination Vaccine Research Development 63

Scienmag

NOVEMBER 9, 2020

Credit: University of Ottawa Researchers from the University of Ottawa and The Ottawa Hospital have been awarded $1,050,000 million from the Canada Foundation for Innovation to support facilities for manufacturing innovative treatments and vaccines for COVID-19.

Manufacturing 95

Manufacturing Vaccination Vaccine Research 95

Scienmag

MARCH 3, 2021

These reactions should not discourage patients from getting the vaccine, say researchers at Massachusetts General Hospital Credit: Massachusetts General Hospital BOSTON – As the speed and scale of vaccinations against the SARS-CoV-2 virus ramps up globally, researchers at Massachusetts General Hospital (MGH) are calling for greater awareness (..)

Vaccination 62

Vaccination Vaccine Research Dermatology 62

Scienmag

APRIL 22, 2021

In February, the researchers introduced […].

Production 84

Production Vaccination Vaccine Protein 84

XTalks

NOVEMBER 6, 2020

Canadian clinical-stage biotech company Symvivo Corporation has developed an oral COVID-19 vaccine that entered clinical trials this week. The first healthy volunteer was dosed with the vaccine in Australia as part of the bacTRL-Spike COVID-19 Phase I clinical trial. Related: Red Meat Allergy Test Gets FDA Clearance. “We

Clinical Trials 75

Clinical Trials Clinical Trials Vaccination Vaccine 75

Delveinsight

AUGUST 6, 2020

Zydus starts phase 2 COVID-19 vaccine trial after clearing safety test. Zydus Cadila has finished a phase 1 clinical trial of its COVID-19 vaccine ZyCoV-D, setting it up to move straight into a 1,000-subject phase 2 study. Zydus has only said that the vaccine was well tolerated by people who received it in the first phase of the trial.

Allergies 53

Allergies Vaccination Vaccine Gene Therapy 53

Scienmag

MAY 26, 2021

Meta-analysis updates findings about common vaccines A new study looking across a large body of research finds further evidence for the safety of vaccines that are Food and Drug Administration-approved and routinely recommended for children, adults and pregnant women.

Vaccination 75

Vaccination Vaccine Drugs Research 75

Pfizer

JULY 19, 2022

1 Adapted Bivalent Vaccine Candidate. 1 Adapted Bivalent Vaccine Candidate. NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced they have completed a submission to the European Medicines Agency (EMA) for an Omicron-adapted bivalent COVID-19 vaccine candidate, based on the BA.1 Tue, 07/19/2022 - 11:22. Booster Series.

Vaccination 100

Vaccination Vaccine Medicine Clinical Trials 100

Scienmag

OCTOBER 27, 2020

To allow meaningful comparison between COVID-19 vaccine candidates and ensure that the most effective candidates are deployed, researchers working on different vaccines should collaborate and assess vaccine efficacy using standardised methods To allow meaningful comparison between COVID-19 vaccine candidates and ensure that the most effective candidates (..)

Vaccination 71

Vaccination Vaccine Research Allergies 71

Scienmag

MARCH 15, 2021

The first vaccine has been administered in a comparative adjuvant trial of DNA prime/protein boost HIV vaccine regimens in Kericho, Kenya Credit: U.S. Military HIV Research Program SILVER SPRING, Md.

Vaccination 68

Vaccination Vaccine Trials DNA 68

Pfizer

JULY 8, 2022

FDA Approval of their COVID-19 Vaccine COMIRNATY® For Adolescents 12 through 15 Years of Age. FDA Approval of their COVID-19 Vaccine COMIRNATY® For Adolescents 12 through 15 Years of Age. The vaccine was previously made available to this age group in the U.S. Fri, 07/08/2022 - 11:48. Pfizer and BioNTech Announce U.S.

FDA Approval 102

FDA Approval Vaccination Vaccine Clinical Trials 102

The Pharma Data

JANUARY 11, 2021

11, 2021 — As the rollout of the COVID-19 vaccines continues, scores of questions are emerging. How do the COVID-19 vaccines work? The COVID-19 vaccines work by teaching the immune system to protect against the virus, experts said. ” Can the vaccines make you sick? How safe and effective are the vaccines?

Vaccination 52

Vaccination Vaccine Allergies Protein 52

Pfizer

SEPTEMBER 28, 2022

5-Adapted Bivalent Vaccine Booster in Children 5 Through 11 Years of Age. 5-Adapted Bivalent Vaccine Booster in Children 5 Through 11 Years of Age. 5-adapted bivalent COVID-19 vaccine for children 5 through 11 years of age. 1-adapted bivalent vaccine, non clinical and manufacturing data from the companies’ 10-µg Omicron BA.4/BA.5-adapted

Vaccination 101

Vaccination Vaccine Medicine Clinical Trials 101

Scienmag

JULY 26, 2021

What The Study Did: Researchers examined the safety of the second dose of the Pfizer-BioNTech or Moderna COVID-19 vaccines in patients who experienced an allergic reaction to the first dose. Authors: Kimberly G. Blumenthal, M.D., of Massachusetts General Hospital in Boston, is the corresponding author.

Vaccination 75

Vaccination Vaccine Research Scientist 75

The Pharma Data

OCTOBER 22, 2020

Moderna has completed enrollment of 30,000 participants for its phase 3 study evaluating COVID-19 vaccine candidate mRNA-1273. The randomized, placebo-controlled trial is being conducted in partnership with the NIH’s National Institute of Allergy and Infectious Diseases and HHS’ Biomedical Advanced Research and Development Authority.

Vaccination 52

Vaccination Vaccine Trials Allergies 52

Scienmag

JULY 26, 2021

Allergists encourage patients to complete their vaccination series BOSTON – In a multi-hospital analysis of individuals who experienced an allergic reaction to their first mRNA COVID-19 vaccine dose, all patients who went on to receive a second dose tolerated it without complications.

Vaccination 70

Vaccination Vaccine Research Allergies 70

The Pharma Data

JANUARY 21, 2021

21, 2021 — Despite scattered media reports of severe allergic reactions to the Pfizer COVID-19 vaccine, a detailed analysis shows that such incidents are very rare, striking just 11 people for every million doses given. The study, compiled by researchers at the U.S. THURSDAY, Jan. 21 in the journal JAMA Insights. 23, about 1.9

Vaccination 52

Vaccination Vaccine Allergies Research 52

Scienmag

JULY 1, 2021

LJI researchers highlight the importance of T cell cross reactivity in stopping severe COVID-19 cases Credit: La Jolla Institute for Immunology LA JOLLA, CA–Researchers at La Jolla Institute for Immunology (LJI) have found that T cells from people who have recovered from COVID-19 or received the Moderna or Pfizer-BioNTech vaccines are still able (..)

Vaccination 74

Vaccination Vaccine Research Allergies 74

Scienmag

JULY 7, 2021

Researchers have produced vaccine-like immune responses to a dangerous bacterium by colonizing 26 healthy volunteers with a related, but harmless, commensal bacterial species.

Bacteria 75

Bacteria Bacterium Immune Response Vaccination 75

Scienmag

SEPTEMBER 1, 2020

Genetic analysis of sequences from more than 27,000 individuals infected with the coronavirus that causes COVID-19 reveals that the virus has mutated minimally since December 2019, suggesting one vaccine would be sufficient to combat global infections.

Genetic Analysis 70

Genetic Analysis Vaccination Vaccine Genetics 70

Scienmag

JUNE 30, 2021

Individuals who contract COVID-19 even after vaccination are likely to have a lower viral load, experience a shorter infection time and have milder symptoms than people who are unvaccinated, according to research that includes data from ongoing University of Arizona Health Sciences studies.

Vaccination 68

Vaccination Vaccine Research Allergies 68

The Pharma Data

NOVEMBER 16, 2020

Moderna Vaccine Shows 94.5 announced on Monday that early results show its COVID-19 vaccine is 94.5 The researchers behind the vaccine said the results were far better than they had hoped. The Moderna vaccine results were analyzed by an independent data safety monitoring board, appointed by the U.S. Professional.

Vaccination 52

Vaccination Vaccine Allergies Research 52

Scienmag

MARCH 25, 2021

The largest study of its kind to date also found benefit for lactating women BOSTON – In the largest study of its kind to date, researchers at Massachusetts General Hospital, Brigham and Women’s Hospital and the Ragon Institute of MGH, MIT and Harvard have found the new mRNA COVID-19 vaccines to be highly effective in […].

Immune Response 69

Immune Response Vaccination Vaccine Antibody 69

XTalks

SEPTEMBER 21, 2023

announced that the first participant has been dosed in a new Phase I trial for an innovative HIV vaccine candidate, VIR-1388. This groundbreaking endeavor has received support from the National Institute of Allergy and Infectious Diseases (NIAID). Vir Biotechnology, Inc.,

Vaccination 59

Vaccination Vaccine Trials Clinical Trials 59

Scienmag

MARCH 2, 2021

New Cleveland Clinic-led research published in mBio Credit: Cleveland Clinic CLEVELAND – Researchers from Cleveland Clinic’s Global Center for Pathogen Research & Human Health have developed a promising new COVID-19 vaccine candidate that utilizes nanotechnology and has shown strong efficacy in preclinical disease models.

Vaccination 59

Vaccination Vaccine Research Development 59

Delveinsight

AUGUST 27, 2020

Moderna’s COVID-19 vaccine triggers an immune response in older adults. Moderna showed robust phase 1 results for its COVID-19 vaccine in adults up to 55 last month. That overexpression of TUBB3 improved chemotherapy’s ability to target and kill the cancer cells in the brain, also reported by the researchers.

Vaccination 53

Vaccination Vaccine Research Trials 53

The Pharma Data

DECEMBER 17, 2020

Advisory Committee Votes to Recommend EUA for Moderna Vaccine. 17, 2020 — The Moderna COVID-19 vaccine received recommendation from a U.S. Food and Drug Administration advisory committee on Thursday, clearing the way for it to become the second COVID-19 vaccine to be granted emergency use authorization. THURSDAY, Dec.

Vaccination 52

Vaccination Vaccine Allergies Clinical Trials 52

The Pharma Data

JANUARY 25, 2021

Anaphylaxis Cases Reported Per Million COVID-19 Moderna Vaccine Shots. cases per million Moderna COVID-19 vaccine doses administered as of Jan. 10, 2021, according to research published in the Jan. The researchers found reports of 1,266 (0.03 anaphylaxis cases per million Moderna COVID-19 vaccine doses administered).

Vaccination 52

Vaccination Vaccine Allergies Research 52

The Pharma Data

JANUARY 7, 2021

Anaphylaxis Cases/Million Doses of Pfizer-BioNTech COVID-19 Vaccine Reported. 23, 2020, researchers determined there were 21 cases of anaphylaxis (11.1 per million doses administered) after receipt of the first dose of the Pfizer-BioNTech COVID-19 vaccine in the United States, according to research published in the Jan.

Vaccination 52

Vaccination Vaccine Allergies Research 52